Paramiwe anti-flu drug leader Nanxin Pharmaceuticals opens requisition

According to the exchange announcement, Hunan Nanxin Pharmaceutical Co., Ltd("Nanxin Pharmaceutical") opened its bid on March 16, and the public offering of 35 million shares, accounting for 25.00% of the total share capital after the issue, of which 997500,000 shares, the purchase price is 34.94 yuan, the issue price-earnings ratio is 55.48 times, the single account purchase limit is 0.95 million shares, the number of purchase supplasts is 500 shares of the whole number, the top purchase needs to match the market value of 9.5 million yuan
Public information shows that Nanxin Pharmaceuticalwas was founded in 2006, has now developed into a drug research and development, production and sales in one of the modern pharmaceutical enterprisesThe company focuses on the research and development, production and marketing of chemical drugs, is committed to major diseases, sudden diseases of new drugs and special effects of drug development and industrialization, in order to better meet the needs of clinical drug use, to serve the "healthy China" strategy
The main recommendations in the 2019 edition of influenza treatment programs are the anti-flu virus drugs of the neuraminidase inhibitor class, which are oseltamivir, zanamivir and paramivirAmong them, Paramive sodium chloride injection for the company's fist products, in the country's municipal and county-level public hospitals occupy a relative advantageSales of individual drugs increased from 70.2389 million yuan in 2017 to 520 million yuan in 2019, and the share of sales increased from 20.21 percent to 51.26 percent
On February 25, Nanxin Pharmaceutical Sactron's IPO was approved by the CSRC to issue no more than 35 million shares publicly, and to invest 410 million yuan in innovative drug research and development projects to advance multi-pipeline drug research and developmentIn addition to Paramive inhalation solution, dry powder inhaler products, Nanxin Pharmaceuticals also includes metafenni and mefloquine hydrochloric acid in the research of drugsThe company expects that the future product structure will be based on new drugs, generic drugs as a supplement to drug innovation capabilities as the company's development engine
Financial data show that from 2017 to 2019 (three years), the company's operating income was RMB34,751.75 million, RMB70,522.07 million and RMB101.422.30 million, respectively, while the net profit attributable to shareholders of the parent company was RMB27.1493 million, RMB53.525 million and RMB91.4743 million, respectivelyWe can see that the company's operating income and net profit in the last three years showed rapid growth
In addition, from the perspective of research and development revenue, Nanxin Pharmaceuticals in the past three years, research and development investment continues to grow, accounting for the proportion of operating income increased year by yearFrom 2017 to 2019 (three-year period), the company's research and development investment was RMB17.4829 million, RMB45.2577 million and RMB71.7649 million, respectively, accounting for 5.03%, 6.46% and 7.08 respectively
The company raised funds to show that the innovation drug research and development project 409.6 million yuan;
It is understood that individual investors to participate in the science and technology board to play new, need to meet three conditions: the application authority before the opening of 20 trading days securities accounts and capital account assets are not less than 500,000 yuan per day (excluding the investor through the financing of securities into the funds and securities);
Among them, the first two conditions are required by the appropriateness of the investors of The Science and Technology Board, and investors who meet these two conditions may apply for trading rights on the basis of the existing A-share securities accountin for Shanghai
In addition, the new Science and Technology board still uses the market value allocation method, eligible investors to open trading rights and hold the Market in Shanghai market value of more than 10,000 yuan to participate in online purchaseEach 5000 yuan market value can be purchased a requisitioning unit, less than 5000 yuan part is not included in the purchase quotaFor each new share requisitioning unit of 500 shares, the requisition quantity shall be 500 shares or an integral multiple, but the requisition quantity shall not exceed one thousandth of the number of initial online issuesIf the above conditions cannot be met, indirect participation may also be made through the public fund.